← Leaderboards
Paul Beisswenger
Preventage Healthcare, Llc
$1,262,074
Attributed
$1,262,074
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $726.4K · FY2014–16$1M$750K$500K$250K$0
'14
'15
'16
Funding mix
By agency
NIH$1,262,074 · 1
By mechanism
R44$1,262,074 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Advanced Glycosylation End Products”
- Ann Marie Schmidt · Beckman Research Institute/City Of Hope$16,947,325
- Jose A Luchsinger · Columbia University Health Sciences$11,327,382
- Gary E Gibson · Winifred Masterson Burke Med Res Inst$10,842,701
- Howard Feldman · University Of California, San Diego$10,098,461
- Ram H Nagaraj · Case Western Reserve University$9,627,678
- Michal Schnaider Beeri · Icahn School Of Medicine At Mount Sinai$7,313,968
Research focus
Advanced Glycosylation End ProductsDiagnostic TestsBaseBehaviorAccountingAffectBiopsyBlindnessBlood TestsCardiovascular DiseasesBiological MarkersCaringChemical StabilityComplications Of Diabetes MellitusCostCost EffectiveCost Of IllnessDiabetes ControlDiabetes MellitusDiabeticDiabetic NephropathyDiabetic PatientDiabetic RetinopathyEpidemic
Grant awards (3)
Diagnostic Biomarkers to Predict Individual Propensity to Diabetic Complications$334,989
R44 · FY2016 · DK · contact PI
Diagnostic Biomarkers to Predict Individual Propensity to Diabetic Complications$726,380
R44 · FY2015 · DK · contact PI
Diagnostic Biomarkers to Predict Individual Propensity to Diabetic Complications$200,705
R44 · FY2014 · DK · contact PI